PF-Atlas › Clinical Trials › NCT07339540
the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
V001-BCMA · China Registry · Early Phase 1
Registry ID
NCT07339540
Phase
Early Phase 1
Status
Recruiting
Drug / intervention
V001-BCMA
Mechanism
China Registry
Sponsor
Tongji Hospital
Start
2025-11-04
Enrollment
45
Locations
1
About this trial
This study is designed as a single arm, open label, single center clinical trial to evaluate the safety, tolerability, efficacy, pharmacokinetic or pharmacodynamic characteristics of the investigational drug V001-BCMA in autoimmune disease.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT07339540 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.